Literature DB >> 28562258

The Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality Improvement Initiative.

Molly Miloslavsky1,2, Marjorie F Galler1, Iman Moawad3, Janet Actis4, Brian M Cummings1,5, Chadi M El Saleeby6,2,7.   

Abstract

BACKGROUND AND OBJECTIVES: There are limited data guiding vancomycin dosing practices in the pediatric population to target the goal troughs recommended by national vancomycin guidelines. In this study, we sought to improve adherence to guideline trough targets through a quality improvement intervention.
METHODS: A retrospective analysis was first conducted to assess baseline performance. A multidisciplinary team then developed and implemented a standardized dosing algorithm recommending 15 mg/kg per dose for mild and moderate infections (goal trough: 10-15 µg/mL) and 20 mg/kg per dose for severe infections (goal trough: 15-20 µg/mL), both delivered every 6 hours (maximum single dose: 750 mg). The impact of the intervention was evaluated prospectively using standard statistics and quality improvement methodology. The outcome measures included the percentage of patients with an initial therapeutic trough and the time to therapeutic trough.
RESULTS: A total of 116 patients (49 preintervention, 67 postintervention) were included. Postintervention, there was a significant increase in the percentage of patients with an initial therapeutic trough (6.1% to 20.9%, P = .03) and in the percentage of patients with initial troughs between 10 and 20 µg/mL (8.2% to 40.3%, P < .001). The time to therapeutic trough decreased from 2.78 to 1.56 days (P = .001), with the process control chart showing improved control postintervention. Vancomycin-related toxicity was unchanged by the intervention (6.1% versus 4.5%; P = .70).
CONCLUSIONS: Using quality improvement methodology with standardized higher initial vancomycin doses, we demonstrated improved adherence to national trough guidelines without noted safety detriment.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28562258     DOI: 10.1542/peds.2016-2423

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital.

Authors:  Kannan Sridharan; Amal Al-Daylami; Reema Ajjawi; Husain Am Al Ajooz
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.022

2.  Vancomycin dosing required to achieve a therapeutic level in children post-surgical correction of congenital heart disease.

Authors:  Yousif S Alakeel; Ghadah A Alanazi; Bushra S Alawbathani; Kadi I Alshutwi; Yazeed S Alahmed
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

Review 3.  Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review.

Authors:  D Donà; E Barbieri; M Daverio; R Lundin; C Giaquinto; T Zaoutis; M Sharland
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-03       Impact factor: 4.887

4.  Steady-state Pharmacokinetics of Vancomycin in Children Admitted to Pediatric Intensive Care Unit of a Tertiary Referral Center.

Authors:  Nitin B Mali; Milind S Tullu; Poorwa P Wandalkar; Siddharth P Deshpande; Vinod C Ingale; Chandrahas T Deshmukh; Nithya J Gogtay; Urmila M Thatte
Journal:  Indian J Crit Care Med       Date:  2019-11

5.  Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children's Hospital.

Authors:  Adam Frymoyer; Hayden T Schwenk; Yvonne Zorn; Laura Bio; Jeffrey D Moss; Bhavin Chasmawala; Joshua Faulkenberry; Srijib Goswami; Ron J Keizer; Shabnam Ghaskari
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

6.  Does vancomycin administered at an empirical dose ensure coverage of pediatric patients against gram-positive pathogens?

Authors:  Frederico Ribeiro Pires; Stefano Ivani de Paula; Artur Figueiredo Delgado; Werther Brunow de Carvalho; Nilo José Coelho Duarte; Ronaldo Morales Júnior; Silvia Regina Cavani Jorge Santos
Journal:  Rev Bras Ter Intensiva       Date:  2020 Jul-Sep
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.